Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924249 | 0.75 | ADORA1 (0.57) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL4621677 | 0.75 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL5498012 | 0.75 | ADORA1 (0.61) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL1566358 | 0.74 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL4985942 | 0.74 | ADORA2A (0.54) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL4981619 | 0.74 | ADORA1 (0.71) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL5200928 | 0.74 | ADORA1 (0.71) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL1565816 | 0.73 | ADORA1 (0.67) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL9729354 | 0.73 | ADORA1 (0.90) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL9729018 | 0.73 | ADORA1 (0.90) | ADORA1ADORA2AADORA2BADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC. | 2008-01-03 | — | — | US | claimed |
| EP-1775297-A2 | Adenosine receptor antagonists and methods of making and using the same | Biogen Idec MA, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ENSINGER CAROL L | 2005-10-06 | — | — | US | claimed |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2003-12-04 | — | — | US | claimed |
| US-6605600-B1 | Diuretics | BIOGEN, INCORPORATED | 2003-08-12 | — | — | US | claimed |
| JP-2003513976-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1230241-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034604-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | BIOGEN IDEC MA INC. | 2010-03-11 | — | — | US | disclosed |
| WO-2009152458-A1 | LIQUID FORMULATION SUITABLE FOR INFUSION COMPRISING AN ADENOSINE RECEPTOR ANTAGONIST FOR TREATING HEART FAILURE AND RENAL INSUFFICIENCY. | BIOGEN IDEC MA INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1775297-A2 | Adenosine receptor antagonists and methods of making and using the same | Biogen Idec MA, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1230241-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ENSINGER CAROL L | 2005-10-06 | — | — | US | disclosed |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6605600-B1 | Diuretics | BIOGEN, INCORPORATED | 2003-08-12 | — | — | US | disclosed |
| EP-1230241-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034604-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | ADORA2A, P2RX3, P2RX6 | ADORA1 8/4885ADORA2A 1/4885ADORA2B 12/4885 |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.